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RHESUS MACAQUE NATURAL CD4 REGULATORY T CELLS EXHIBIT
DECREASED PROLIFERATION BUT ENHANCED SUPPRESSION AFTER
PULSING WITH SIROLIMUS
Singh, K.1, Stempora, L.1, Kirk, A.D.1, Larsen, C.P.1, Blazar, B.B.2,
Kean, L.S.1,3 1Emory University School of Medicine, Atlanta, GA; 2Uni-
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Although regulatory T cells (Tregs) suppress alloimmunity, diffi-
culties in their large-scale production and in maintaining their sup-
pressive function after expansion have so far limited their usefulness
in overcoming allograft rejection and graft-versus host disease. Here
we have used our established non-human primate model to demon-
strate that significant Treg expansion (up to 600-fold in 21 days) can
be achieved and suppressive capacity enhanced by exposing Tregs to
a short burst of sirolimus. Using an in vitro CFSE-MLR based sup-
pression assay we show that Tregs significantly inhibit allo-prolifer-
ation of both CD4+ and CD8+ T cells (3.5 and 3.0-fold inhibition of
proliferation, respectively), as well as their central memory and effec-
tor memory subpopulations (3.0-, 2.9-, 2.4- and 2.7-fold inhibition
of CD4+ and CD8+ Tcm and Tem proliferation, respectively). We
further show that Tregs can be combined in vitro with CTLA4-Ig
to enhance the inhibition of alloproliferation that occurred with ei-
ther agent alone (4.8-fold inhibition of CD8 T cell proliferation
with Tregs + CTLA4Ig, compared to 3.4-fold or 2.0-fold with Tregs
or CTLA4Ig alone, respectively). Importantly, we have found that
the suppressive activity of ex-vivo expanded Tregs could be further
enhanced by pulsing with sirolimus. Thus, while long-term culture
of Tregs in the presence of sirolimus (1-1000 nM) profoundly in-
hibited Treg expansion (50-800 fold inhibition of expansion in the
presence of 1-1000 nM sirolimus), a 48 hour pulse of sirolimus
(100 nM) on days 20-21 of culture completely preserved Treg yields
while significantly enhancing their suppressive function against both
CD4 and CD8 alloproliferation (p\ 0.01). Sirolimus pulsed Tregs
(SPTs) undergo fewer rounds of proliferation in anMLRwhen com-
pared with unpulsed Tregs (p5 0.015), suggesting that Treg-medi-
ated suppression may be inversely related to their proliferative
capacity. SPTs also display increased expression of CD25 (p 5
0.04) and total CTLA4 (p 5 0.009) compared to unpulsed Tregs,
implicating signaling through both of these molecules in their en-
hanced function. Our results suggest that the creation of SPTs
may provide a novel avenue to enhance Treg-based suppression of
alloimmunity, in amanner amenable to large-scale ex-vivo expansion
and combinatorial therapy with novel, costimulation-blockade-
based immunosuppression strategies.2
GENE THERAPY FOR HEMOPHAGOCYTIC LYMPHOHISTIOCYTOSIS
(HLH): FIXING A CRITICAL ‘CIRCUIT BREAKER’ IN THE IMMUNE SYSTEM
Carmo, M.1, Arumugam, P.2, Tiwari, S.2, Thrasher, A.1, Risma, K.2,
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In addition to its well-known role in host defense, perforin-depen-
dent cytotoxicity also has a critical immune regulatory function.
Genetic defects of perforin underlie many cases of hemophagocytic
lymphohistiocytosis (HLH), a disorder of extreme immune activa-
tion. While the initial treatment of HLH is largely focused on sup-
pressing dangerous inflammation, HCT is required to correct the
underlying immune defect. Unfortunately, mortality after HCT inpatients with HLH is unusually high for a non-malignant disorder,
ranging from 20 to 50%.
We previously reported that transplantation of wild type (WT)
bone marrow into perforin deficient (prf-/-) mice rescues them
from the subsequent development of HLH after viral challenge
with lymphocytic choriomeningitic virus (LCMV). In this model,
perforin-dependent immune regulation appears to function in trans,
with a critical threshold of 10%WT chimerism required to protect
animals from HLH. This low threshold is consistent with reports of
very limited numbers of patients with long termmixed chimerism af-
ter HCT who appear to be protected from HLH recurrence. These
data have also provided a clear target for gene therapy efforts.
We have begun to test the utility of autologous gene correction
using lentivirus vectors in this model system. Hematopoietic stem
and progenitor cells (HSC) from prf-/- mice were transduced
with lentivirus vectors expressing perforin under the control of
ubiquitous or tissue-specific promoters. When transduced HSC
were transplanted into lethally irradiated prf-/- mice, we have ob-
served levels of in vivo gene correction ranging from 10-80%, de-
pending on the promoter and transduction protocols utilized. We
find that the transduced NK cell progeny display significant correc-
tion of their cytotoxic defects. Challenge of gene corrected mice
with LCMV infection is ongoing. The ability of gene corrected
HSC to reestablish a normal pattern of cytokine production, T
cell activation, and protection from HLH after LCMV infection
will be presented.
Because normal perforin expression in only a fraction of lympho-
cytes is sufficient to rescue individuals fromHLH, this disorder is an
attractive target for gene therapy approaches. Demonstration of long
term gene correction and rescue fromHLH in our animal model will
pave a path for translational efforts testing gene therapy for HLH in
clinical trials.
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PLASMA CONCENTRATION OF SUPPRESSOR OF TUMORIGENICITY 2
(ST2), THE IL33 RECEPTOR, AT INITIATION OF GRAFT VERSUS HOST DIS-
EASE THERAPY PREDICTS DAY 28 RESPONSE AND DAY 180 SURVIVAL
POST-TREATMENT
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Acute graft-versus-host disease (GVHD) is the primary limita-
tion of allogeneic hematopoietic cell transplantation. Current diag-
nostic tests do not predict a patient’s response to therapy,
particularly at GVHD onset, when risk-stratification is most bene-
ficial. We hypothesized that biomarkers discovered using a previ-
ously described intact proteomic analysis system (IPAS) approach
(Paczesny et al. 2010) will discriminate between therapy responsive
(resolution or improvement of GVHD by day (D) 28 post-therapy
initiation) and unresponsive (absence of complete or partial re-
sponse) patients.
We first compared pooled plasma taken at D16 6 5 post-therapy
from 10 responders (R) and 10 non-responders (NR) using IPAS as
a discovery engine. Five of 10 candidate biomarkers elevated at
least 1.5 fold in NR were also significantly elevated when measured
individually by ELISA (ST2, IL1R2, MIF, LYVE, and Lipocalin).
These and 6 previously validated diagnostic GVHD biomarkers
(IL2Ra, TNFR1, HGF, IL8, Elafin, a skin-specific marker, andS201
Table 1. ST2 Concentration Predicts D28 Response and D180 NRM
A. ST2 Concentrations Outperform a 7 Biomarker Panel in Predicting D28 Response
Univariate Panel ST2 Alone
Odds Ratio p-value Odds Ratio p-value Odds Ratio p-value
Conditioning Intensity (Full vs. Reduced) 1.7 0.04 1.7 0.03 1.6 0.05
HLA Match (Mismatched vs. Matched) 1.5 0.07 1.4 0.2 1.3 0.3
Onset GVHD Grade (3-4 vs. 1-2) 2.2 0.001 2.2 0.003 2.0 0.008
Panel (5 of 7 biomarkers 50% above the responders’ median) 2.2 <0.001 1.9 0.004 n/a
ST2 Alone (50% above the responders’ median) 3.0 <0.001 n/a 2.6 <0.001
Panel 5 Multivariate analysis after adjustment for conditioning intensity, HLA match and onset GVHD grade
ST2 alone 5 Multivariate analysis after adjustment for conditioning intensity, HLA match and onset GVHD grade
B. Risk Stratification with ST2 and GVHD Onset Grade for 180 NRM
ST2 & Onset GVHD Grade D180 post-therapy NRM Hazard Ratio compared to (a) p-value
(a) Low ST2 & Grade 1-2 (n 5 130) 11%
(b) Low ST2 & Grade 3-4 (n 5 22) 9% 0.8 0.8
(c) High ST2 & Grade 1-2 (n 5 165) 28% 2.9 <0.001
(d) High ST2 & Grade 3-4 (n 5 64) 64% 9.0 <0.001
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throughput ELISA at therapy initiation (D0) in a validation set
of 381 patients with acute GVHD and treated with systemic
steroids.
After adjusting for HLA match, conditioning intensity, and onset
GVHD grade, the clinical characteristics predictive of D28 non-
response (Table 1A), multivariate analysis of the 11 proteins showed
that 3 markers predictedD28 non-response (ST2, p5 0.001; IL1R2,
p 5 0.05; and IL8, p 5 0.03) and 7 predicted D180 post-therapy
overall survival (ST2, p 5 0.004; IL1R2, p 5 0.08; IL8, p 5 0.06;
Elafin, p 5 0.07; MIF, p 5 0.05; TNFR1, p 5 0.02; and Reg3a,
p 5 0.001 in the gut-GVHD subset). Using logistic regression, weexamined the ability of both the 7 biomarkers and ST2 alone to pre-
dict forD28 non-response, as ST2was themost significant marker in
all previous analyses. D0 ST2 concentrations outperformed the
panel in predicting D28 response (Table 1A) and predicted D180
non-relapse mortality (NRM), independent of GVHD onset grade
(Table 1B). In conclusion, soluble ST2, the form measured by
ELISA, is a decoy receptor that may act in the pathophysiology of
resistant GVHD by driving the Th2 phenotype toward Th1. ST2
concentrations obtained at initiation of GVHD therapy significantly
enhance the accuracy of outcome prediction independent of GVHD
grade and may allow for early identification of patients at risk for
subsequent non-response and mortality.
